The effect of Alhagi Pseudalhagi distillate on ureteral stone expulsion

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138804172134N1

Enrollment

100

Registered

2009-12-29

Start date

2009-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ureteral stone. Calculus of ureter

Interventions

Intervention 1: The control group receive Hydrochlorothiazide (25 mg/day), Tamsulosin (0.4 mg/day), Diclofenac sodium suppository (100 mg PRN), and Tramadol inj. (50 mg IM PRN). Intervention 2: The in

Treatment - Drugs

The control group receive Hydrochlorothiazide (25 mg/day), Tamsulosin (0.4 mg/day), Diclofenac sodium suppository (100 mg PRN), and Tramadol inj. (50 mg IM PRN).

The intervention group receive Hydrochlorothiazide tablets (25 mg/day), Tamsulosin capsules (0.4 mg/day), Diclofenac sodium suppository (100 mg PRN), Tramadol inj. (50 mg IM PRN), and 150 ml/day Alha

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: having ureteral stones ? 6 mm, not severe hydronephrosis, age more than 20 yr and less than 60 yr, no signs of UTI or fever according to physical findings and urine analysis, no known renal diseases according to history and preliminary laboratory exams, no mandatory restriction of fluids due to an underlying disease, no bilateral ureteral stones, not having a single kidney, no known allergic reaction to Alhagi Pseudalhagi distillate or gum, not being pregnant, and body weight between 50 to 100 kg. Exclusion criteria: patients' reluctance to continue participating in the study, no follow up visits, progressive hydronephrosis during follow up, occurrence of fever or UTI during follow up, repeated bouts of unbearable ureteral colics during follow up, allergic reactions or complications due to the treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ureteral stone passage. Timepoint: 2 and 4 weeks after commencement of therapy. Method of measurement: According to patients' report.	—

Secondary

Measure	Time frame
Time to stone passage. Timepoint: 2 and 4 weeks after commencement of therapy. Method of measurement: by asking the patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Cyrus

Arak University of Medical Sciences

cyrus@arakmu.ac.ir+98 86 1222 1041

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026